


MEDICINAL PRODUCTS 2020

NEOGEN CORP Rank 2 of 52









MEDICINAL PRODUCTS 2020

NEOGEN CORP Rank 2 of 52 RealRate



The relative strengths and weaknesses of NEOGEN CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEOGEN CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 73% points. The greatest weakness of NEOGEN CORP is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 3.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 160%, being 164% points above the market average of -4.3%.

Input Variable	Value in 1000 USD
Assets, Current	449,529
Assets, Non-Current	171,364
General and Administrative Expense	333,287
Goodwill	0
Liabilities, Current	38,251
Liabilities, Non-Current	3,972
Other Assets	0
Other Compr. Net Income	-1,894
Other Expenses	12,783
Other Liabilities	15,618
Other Net Income	4,865
Other Revenues	414,186
Property, Plant and Equipment, Net	74,847
Research and Development	12,805

Output Variable	Value in 1000 USD
Liabilities	57,841
Assets	695,740
Expenses	358,875
Revenues	414,186
Stockholders Equity	637,899
Net Income	60,176
Comprehensive Net Income	59,229
Economic Capital Ratio	160%

